PT-141Check methods and identity
What the Current US Bremelanotide Label Covers
1 numbered sourceSource years 2026
Peptides are short chains of amino acids held together by peptide bonds. Some can act at receptors that respond to the body's own signals. PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication. [1]
The labeled indication concerns acquired, generalized hypoactive sexual desire disorder in premenopausal women. In plain language, it refers to a persistent problem with low desire that developed after a period without that problem, is not limited to a particular situation, and causes marked distress or difficulty. The label excludes cases explained by other medical or psychiatric conditions, relationship problems, or effects of a medicine or other substance. These qualifiers matter because a change in desire can have different causes and does not by itself define the disorder studied. [1]
The label also states that the product is not indicated for postmenopausal women or men, and is not indicated to enhance sexual performance. Those limits distinguish the approved prescription indication from other claims sometimes made under the PT-141 name. The research molecule name alone also does not establish that a particular preparation is the approved product. [1]
The label is a current source for the product's indication and safety information, not evidence for every proposed use of the molecule. When reading an article about PT-141, check which product was tested, how the study defined its population and which outcome it measured. Those details make it possible to describe the actual evidence without generalizing from a narrowly evaluated use. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
